Mucins are essential structural components of the tear film, forming the critical interface between the aqueous layer and the ocular surface epithelium. This mucin layer—often described as the “foundation” of the tear film—ensures adhesion, stability, and even distribution of tears across the cornea and conjunctiva. Deficiencies in mucin production disrupt this delicate architecture, leading to premature tear film breakup, increased epithelial vulnerability, and persistent symptoms such as dryness, grittiness, and ocular surface damage. Clinical evidence confirms that mucin abnormalities are prevalent across a broad spectrum of dry eye disease (DED), particularly in patients with underlying ocular surface inflammation.
For individuals whose dry eye stems from mucin insufficiency, the therapeutic goal extends beyond symptomatic relief: it requires restoring endogenous mucin synthesis. Among available pharmacologic options, low-concentration cyclosporine ophthalmic emulsion has emerged as a first-line, mechanism-driven therapy—endorsed by both national and international clinical guidelines for its dual anti-inflammatory and mucin-promoting effects.
1. Stimulating Endogenous Mucin Secretion to Reinforce Tear Film Integrity
The 2024 Consensus Statement on Clinical Diagnosis and Management of Dry Eye Disease, published by the Corneal Disease Group of the Chinese Ophthalmological Society, explicitly states that low-dose cyclosporine A (0.05%) enhances secretion of both aqueous tears and transmembrane and secreted mucins—including MUC5AC from conjunctival goblet cells. By mitigating chronic inflammation at the ocular surface, cyclosporine preserves goblet cell density and function, thereby supporting natural mucin production. Zirun Cyclosporine Ophthalmic Emulsion (II) exemplifies this approach: rather than merely supplementing the tear film, it targets the root cause—dysfunctional goblet cells—to rebuild the mucin layer from within.
2. Facilitating Epithelial Repair Through Inflammatory Control
A bidirectional relationship exists between mucins and the corneal and conjunctival epithelium: epithelial injury suppresses mucin expression, while mucin deficiency impairs epithelial barrier function and delays healing. The 2026 *Clinical Practice Guidelines for Dry Eye: A Comprehensive Approach* identifies 0.05% cyclosporine ophthalmic emulsion as a recommended first-line treatment for inflammatory dry eye associated with reduced tear production. Zirun Cyclosporine Ophthalmic Emulsion (II) is specifically indicated for patients with keratoconjunctivitis sicca linked to ocular surface inflammation. Its immunomodulatory action not only dampens T-cell–mediated inflammation but also creates a permissive microenvironment for epithelial regeneration and goblet cell recovery—establishing a self-sustaining cycle of ocular surface restoration.
3. Delivering Sustained Tear Film Stability and Symptom Reduction
Clinically, improved mucin coverage correlates directly with prolonged non-invasive tear break-up time (NIBUT) and reduced symptom recurrence. Unlike conventional artificial tears—which provide transient hydration without addressing underlying pathophysiology—cyclosporine-based therapy yields durable improvements in tear film kinetics. Patients commonly report diminished frequency and severity of dryness, foreign-body sensation, and visual fluctuation, translating into enhanced functional vision and quality of life during daily activities.
Zirun Cyclosporine Ophthalmic Emulsion (II) represents a targeted, evidence-based strategy for mucin-deficient dry eye. By concurrently suppressing inflammation and stimulating endogenous mucin synthesis, it addresses both the trigger and the structural deficit—offering not just short-term comfort, but long-term ocular surface stabilization.
Supportive Care Recommendations
To optimize therapeutic outcomes, clinicians advise avoiding preservative-containing eye drops, which may exacerbate goblet cell toxicity; ensuring adequate dietary vitamin A intake to support epithelial integrity; minimizing mechanical trauma such as eye rubbing; and undergoing periodic assessment—including corneal and conjunctival staining and NIBUT measurement—to objectively monitor mucin layer functionality and treatment response.
Frequently Asked Questions
Q: Can mucin-supplementing artificial tears be used alone?
A: While mucin-enhanced lubricants may offer temporary symptomatic relief in mild cases, they do not resolve the underlying inflammatory drivers of goblet cell dysfunction. For patients with inflammatory mucin deficiency, combination therapy—including anti-inflammatory agents like cyclosporine—is necessary to achieve sustained improvement. Treatment decisions should always be guided by comprehensive clinical evaluation.
Q: How long before mucin-related improvements become clinically apparent?
A: Goblet cell recovery and measurable increases in tear film stability typically require consistent therapy for 8–12 weeks. Most patients demonstrate significant extension of NIBUT and reduction in symptom burden after three months of adherence to prescribed dosing. Continued use supports progressive epithelial and goblet cell normalization.
In summary, for dry eye rooted in mucin deficiency, low-concentration cyclosporine ophthalmic emulsion—such as Zirun Cyclosporine Ophthalmic Emulsion (II)—offers a pathophysiologically grounded intervention: one that rebuilds the tear film’s foundational layer while resolving the inflammatory milieu that perpetuates ocular surface disease.